Results 91 to 100 of about 64,857 (161)

The secretory protein, CLCF1, improves cholestatic liver disease by inhibiting hepatic bile acid synthesis and promoting bile acid excretion. [PDF]

open access: yesCommun Biol
Liu M   +12 more
europepmc   +1 more source

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer. [PDF]

open access: yesSignal Transduct Target Ther
Chibaudel B   +19 more
europepmc   +1 more source

Development and validation of a novel panel of CSF biomarkers for Alzheimer's disease. [PDF]

open access: yesAlzheimers Res Ther
Hok-A-Hin YS   +9 more
europepmc   +1 more source

Dysbiosis in the Gut-Liver Axis Is Associated With Low Bone Mass During Murine Cholestasis. [PDF]

open access: yesFASEB J
Hutchison B   +7 more
europepmc   +1 more source

Cost effectiveness of the Texas wildlife rabies Border Maintenance Zone. [PDF]

open access: yesPLoS Negl Trop Dis
Shwiff S   +4 more
europepmc   +1 more source

The feasibility of conducting an impact evaluation of the Dedicated Drug Court pilot [PDF]

open access: yes, 2009
McSweeney, Tim   +4 more
core  

Genetic ablation of interleukin-17A augments fibrosis in a mouse model of cholestatic liver injury. [PDF]

open access: yesPLoS One
Kitagataya T   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy